Novartis | NOVN - Deudores Comerciales





Deudores Comerciales Cambio Fecha
AbbVie USD 12.59B 180M 2025-12
Alcon AG USD 2.54B 596M 2025-12
Almirall EUR 175.93M 17.87M 2025-12
Amgen USD 9.14B 432M 2026-03
AstraZeneca USD 17.88B 1.17B 2026-03
Autolus Therapeutics Ltd USD 75.79M 15.57M 2025-12
Bayer EUR 14.19B 720M 2025-12
Biogen USD 1.79B 76.6M 2026-03
Bristol-Myers Squibb USD 14.36B 164M 2026-03
Eli Lilly USD 21.18B 1.02B 2026-03
Fresenius EUR 4.08B 18M 2025-09
Fresenius Medical Care EUR 3.66B 382.33M 2025-12
Galapagos EUR 199.75M 122.08M 2025-12
Genmab DKK 1.17B 119M 2025-12
Gilead Sciences USD 4.91B 182M 2025-12
GlaxoSmithKline GBP 7.94B 178M 2026-03
GRIFOLS EUR 852M 244.52M 2025-12
Hikma Pharmaceutical USD 1.08B 27M 2025-12
J&J USD 21.33B 3.72B 2025-12
Lonza CHF 1.78B 55M 2025-12
Merck EUR 4.44B 293M 2025-12
Merck USD 11.78B 345M 2025-12
Novartis USD 12.29B 3.3B 2025-12
Novartis USD 12.29B 3.3B 2025-12
Novo Nordisk DKK 95.05B 2.4B 2025-12
Orion EUR 699.6M 270.4M 2026-03
Pfizer USD 18.12B 2.02B 2025-09
Philips EUR 3.8B 266M 2025-12
Recordati EUR 699.76M 472K 2025-09
Regeneron Pharmaceuticals USD 5.73B 10.1M 2026-03
Roche Holding CHF 11.9B 460M 2025-12
Sanofi EUR 482M 85M 2026-03
UCB EUR 1.97B 54M 2025-12